MYRXBOX / EVIDENCE-BASED GLP-1 COMPARISON
They are both once-daily semaglutide tablets. But the 2026 U.S. labels describe different treatment purposes, strengths and dosing schedules. Here is what the names on the box actually mean.
Updated October 2026 · Focus: current U.S. product labeling
THE 30-SECOND ANSWER
DIABETES
3 mg · 7 mg · 14 mg
U.S. tablets labeled for adults with type 2 diabetes, including blood-glucose control and certain cardiovascular-risk reduction indications.
WEIGHT MANAGEMENT
1.5 mg · 4 mg · 9 mg · 25 mg
U.S. oral semaglutide product with approved weight-management and cardiovascular-risk reduction uses in qualifying adults.
2026 NAME UPDATE
1.5 mg · 4 mg · 9 mg
A separate oral semaglutide label for type 2 diabetes. It adds a third name to the comparison, but it is not a weight-management substitute for Wegovy.
Key point: The number of milligrams is not a safe shortcut for switching brands or deciding which medicine is stronger. Formulation, approved use and the prescriber’s plan all matter.
WEGOVY TABLETS VS RYBELSUS
The table below summarizes current U.S. prescribing information. Local labels and availability outside the United States can differ.
| Comparison | Rybelsus tablets | Wegovy tablets |
|---|---|---|
| Active ingredient | Semaglutide | Semaglutide |
| Main U.S. labeled use | Type 2 diabetes: glycemic control and reducing major cardiovascular events in certain high-risk adults with diabetes | Long-term weight management in qualifying adults; also cardiovascular-risk reduction in certain adults with overweight or obesity |
| Tablet strengths | 3 mg, 7 mg, 14 mg | 1.5 mg, 4 mg, 9 mg, 25 mg |
| Schedule | Once daily | Once daily |
| Starting step in label | 3 mg for the first 30 days; initiation, not effective for glycemic control | 1.5 mg for the first 30 days, with later dose steps in the label |
| Later dose plan | 7 mg; sometimes 14 mg if additional glucose control is needed | 4 mg, 9 mg, then 25 mg as the stated adult maintenance dose |
| Before breakfast | Empty stomach, up to 4 oz of plain water; wait at least 30 minutes before food, drink or other oral medicines | Same empty-stomach and 30-minute waiting instructions |
| Can the tablets be swapped mg for mg? | No. Prescription and formulation changes need a clinician. | No. Do not copy a dose from a different brand or formulation. |
THE 2026 DOSE DECODER
A tablet labeled 25 mg is not automatically “the same medicine at almost double the strength.” These products have different approved treatment plans, and the numbers do not describe a head-to-head potency ranking.
Do not treat this illustration as a dosing guide. It shows the strengths named in U.S. labeling, not a plan for starting, changing or combining medication. Only a licensed prescriber can select or change a regimen.
For a closer look at the diabetes-strength tablets, read Rybelsus 3 mg vs 7 mg vs 14 mg.
EASY TO MISS IN 2026
The 2026 U.S. prescribing document groups Rybelsus and Ozempic tablets under oral semaglutide, but it lists different strength families: Rybelsus at 3, 7 and 14 mg; Ozempic tablets at 1.5, 4 and 9 mg. These are not substitutable milligram for milligram.
Wegovy is a separate brand with a tablet treatment plan for weight management. That makes three names worth checking on any prescription: brand, tablet strength and approved purpose. The same active ingredient does not make every package interchangeable.
Quick label check: Read the exact product name and strength on your prescription and box. If the name or strength differs from what you expected, ask the pharmacist before taking it.
Read more: Semaglutide in the MyRxBox medicine glossary.
WHAT THE CLINICAL RESEARCH SHOWS
A well-known Wegovy pill study is OASIS 4, which tested oral semaglutide 25 mg against placebo in adults with obesity or overweight who did not have diabetes. It did not directly compare Wegovy tablets with Rybelsus tablets.
WEGOVY TABLET GROUP
−13.6%
Mean body-weight change at week 64 in OASIS 4.
PLACEBO GROUP
−2.2%
Mean body-weight change at week 64 in the same trial.
The trial included 307 participants and diet and activity support. These group averages are not a prediction for an individual person. You cannot use separate trials in different populations to claim that one brand is more effective than the other.
Read the OASIS 4 clinical trial abstract for study details.
THE MORNING RULE
Both U.S. tablet labels describe a specific empty-stomach routine. The timing matters because oral semaglutide absorption is sensitive to food and other beverages.
01
The labeled routine starts first thing in the morning before food.
02
Swallow the tablet whole with no more than 4 fluid ounces of plain water. Do not crush or chew.
03
Wait at least 30 minutes before eating, drinking other beverages or taking other oral medicines.
If you take thyroid medicine, insulin, or other prescription products, ask your clinician or pharmacist to review your complete schedule. Never adjust it based only on a website.
SAFETY FIRST
Common side effects can include nausea, vomiting, diarrhea, abdominal pain and constipation. Serious problems can include pancreatitis, dehydration-related kidney injury, gallbladder disease, severe allergic reactions and low blood sugar when used with some diabetes medicines.
Boxed warning: Semaglutide caused thyroid C-cell tumors in rodents; whether this risk applies to humans is unknown. These products must not be used by people with a personal or family history of medullary thyroid carcinoma (MTC) or MEN2. Review the official label with your prescriber.
Do not combine oral semaglutide brands. The Wegovy label advises against using Wegovy with another semaglutide-containing medicine or another GLP-1 receptor agonist. A change between products should be managed by the prescribing clinician.
If you see suspicious low-cost GLP-1 offers, start with 7 warning signs of fake GLP-1 medicines.
RELATED MYRXBOX MEDICINE PAGES
These are the Rybelsus strengths currently listed on MyRxBox. The links below are for checking product descriptions and prescribed-strength details—not for choosing a dose yourself.
Also see the diabetes medicine price index for published product prices and pack sizes. Prices change and are not a measure of treatment suitability.
PEOPLE ALSO ASK
No. Both contain semaglutide, but current U.S. labels describe different indications, available strengths and dose plans. Rybelsus is labeled for type 2 diabetes; Wegovy tablets have weight-management and certain cardiovascular-risk uses.
The FDA approved Wegovy oral tablets on December 22, 2025. The product entered the U.S. market in early 2026.
No established milligram-for-milligram substitution is provided in the product labels. Do not use the numbers alone to switch or compare a prescribed dose.
The current U.S. labeling lists Rybelsus tablets at 3, 7 and 14 mg and Ozempic tablets at 1.5, 4 and 9 mg. Both concern adults with type 2 diabetes, but the formulations cannot be swapped milligram for milligram.
The Wegovy prescribing information advises against combining Wegovy with other semaglutide products or another GLP-1 receptor agonist. Ask the prescribing clinician about any medication changes.
Switching needs individual medical review. The manufacturer states that it has not carried out trials that establish a standard Rybelsus-to-Wegovy switching regimen.
Weight changes can occur during Rybelsus treatment, but weight management is not the same as its U.S. labeled purpose. Outcomes depend on individual factors, and results from different studies should not be treated as a direct comparison.
Both have evidence supporting their labeled uses, but they have different schedules and formulations. Numbers from separate clinical trials are not a direct head-to-head comparison.
No global approval or supply status should be assumed from a U.S. FDA approval. Check the regulator and licensed pharmacy in your country for current availability.
CONTINUE READING ON MYRXBOX
How oral GLP-1 medicines fit into diabetes care.
For more definitions, see semaglutide in the medicine glossary or browse the diabetes medicine category.
PRIMARY SOURCES
Medical information only. This article does not diagnose, prescribe or replace medical care. FDA approvals described here are U.S.-specific. Check the latest official labels and speak with a licensed healthcare professional about individual treatment decisions.
MyRxBox article · Updated October 30, 2026